During the ongoing COVID-19 pandemic contact with the healthcare system for cancer treatment can increase risk of infection and associated mortality. Treatment recommendations must consider this risk for elderly and vulnerable cancer patients. We re-analyzed trials in elderly glioblastoma GBM patients incorporating COVID-19 risk in order to provide a quantitative framework for comparing different radiation RT fractionation schedules on patient outcomes. A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly.